Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon beta-Reference-Cited by-同舟云学术

Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon beta

Published:2017-09-05 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Haile Lydia Asrat,Polumuri Swamy Kumar,Rao Roshni,Kelley-Baker Logan,Kryndushkin Dimitri,Rajaiah Rajesh,Israely Tomer,Rao V. Ashutosh,Verthelyi Daniela

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-09981-w.pdf

Reference56 articles.

1. Shankar, G., Pendley, C. & Stein, K. E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25, 555–561 (2007).

2. Rosenberg, A. S., Verthelyi, D. & Cherney, B. W. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. J Pharm Sci 101, 3560–3567 (2012).

3. Parenky, A. et al. New FDA draft guidance on immunogenicity. AAPS J 16, 499–503 (2014).

4. Kishnani, P. S. et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab 117, 66–83 (2016).

5. Schellekens, H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14, 191–202 (2008).

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody (PART 1A – Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis PART 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2024-05-02

2. Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis;Clinical Immunology;2023-12

3. Immunogenicity Study of Biosimilar Candidates;Drug Development and Safety [Working Title];2023-02-27

4. Recent Advancement of Nanostructured Materials for Clinical Challenges in Vaccinology;Nanovaccinology;2023

5. Assessment of innate immune response modulating impurities in glucagon for injection;PLOS ONE;2022-11-21